SCHEMBL8048686

SCHEMBL8048686

COc1ccccc1C(=O)Nc1n[nH]c2nc(-c3cnn4ccccc34)c(F)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.51
EGFR P00533 4/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
ROCK1 Q13464 2/20 0.42
IGF1R P08069 1/20 0.41
FGFR4 P22455 4/20 0.41
EPHB3 P54753 1/20 0.41
ABL1 P00519 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CDC7 O00311 1/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40
HIPK2 Q9H2X6 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
DRD4 P21917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8048684 0.90 ROCK1 (0.46) IRAK4LMNAHTTROCK1FGFR4
SCHEMBL8043054 0.90 EPHB3 (0.47) IRAK4LMNAHTTROCK1FGFR4
SCHEMBL8042726 0.88 EPHB3 (0.46) IRAK4EGFRLMNAHTTROCK1
SCHEMBL13099662 0.87 IRAK4 (0.45) IRAK4LMNAHTTROCK1EPHB3
SCHEMBL13099760 0.87 ROCK1 (0.42) IRAK4EGFRLMNAHTTROCK1
SCHEMBL8044716 0.86 EPHB3 (0.48) IRAK4LMNAHTTROCK1EPHB3
SCHEMBL13099704 0.85 CDK2 (0.42) IRAK4LMNAHTTROCK1EPHB3
SCHEMBL13099711 0.84 EPHB3 (0.40) IRAK4LMNAHTTROCK1IGF1R
SCHEMBL3234709 0.84 FGFR4 (0.46) IRAK4ROCK1FGFR4EPHB3
SCHEMBL8042730 0.83 EGFR (0.41) IRAK4EGFRLMNAHTTROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
WO-2009038385-A2 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 IRAK4 731/4885EGFR 1045/4885LMNA 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.